Summit Therapeutics and Akeso said their PD-1xVEGF bispecific antibody ivonescimab beat BeiGene’s PD-1 blocker Tevimbra in a ...

Ascletis Pharma's obesity drug ASC30 shows puzzling results in Phase 1b trial, with high dose less effective than lower doses ...

A small Northwestern University spinout attempting to develop a twist on biologics has pulled together a $30 million Series A ...

Repertoire Immune Medicines makes a major announcement in April. And this year is no different. The Flagship ...

Eli Lilly on Thursday filed lawsuits against four telehealth companies over their sale of compounded versions of the GLP-1 ...

Boehringer Ingelheim has inked a research collaboration with Tessellate Bio to develop precision medicines for cancers that ...

A Bay Area protein design startup wants to build more potent antibody-drug conjugates, and is starting with $20 million in seed funding. The company, Synthetic Design Lab, was founded by ...

Fujifilm Diosynth Biotechnologies' bet on its North Carolina biologics facility is paying off, as Regeneron plans to shell ...

British drugmaker AstraZeneca is rejoining the drug industry's major US lobbying group, PhRMA, roughly two years after ...

Superpower raises $30M Series A led by Forerunner to expand health testing service offering blood biomarker analysis and app ...

Matter Bio, co-founded by George Church, partners with scientists to study longevity genes in centenarians and long-lived ...

Pharma companies stockpile drugs in US ahead of expected Trump tariffs, while execs warn of R&D cuts and manufacturing ...